New Brunswick, NJNCT06564038Now EnrollingIRB Ready

B-cell Lymphoma Clinical Trial in New Brunswick, NJ

Access cutting-edge b-cell lymphoma treatment through this phase 1/2 clinical trial at a research site in New Brunswick. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this New Brunswick location

Preparing your pre-screening questions…

Expert Care in New Brunswick

Access b-cell lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related b-cell lymphoma treatment provided free

Apply for This New Brunswick Location

Check if you qualify for this b-cell lymphoma clinical trial in New Brunswick, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Brunswick

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Brunswick site if eligible
  4. 4Begin participation

About This B-cell Lymphoma Study in New Brunswick

The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Master Inclusion Criteria applicable to all substudies:
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
Contraception use during treatment and at least 90 days after final dose.
Confirmed CD19 expression if prior anti-CD19 therapy. Substudy 1 Specific Inclusion Criteria:
Participants with CLL must require treatment according to the international workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria.
SLL: at least 1 measurable site per Lugano.
Absolute lymphocyte count (ALC) \<25000 cells/mcL.
Cohort 1A and 1C: at least 2 prior lines of systemic therapy for CLL/SLL.
Cohort 1B: at least 1 prior line of therapy and is bruton tyrosine kinase inhibitor (BTKi)-sensitive. Substudy 2 Specific Inclusion Criteria:
MCL diagnosis per WHO.
Clinical Stage II, III, or IV by Ann Arbor Classification.
At least 1 measurable site per Lugano.
ALC \< 25000 cells/mcL.
Cohort 2A and 2C: Relapse or progressed after 2 or more lines of therapy including BTKi. Substudy 3 Specific Inclusion Criteria:
At least 1 measurable site as per Lugano.
Left ventricular ejection fraction (LVEF) ≥50%.
Participant must be no older than 79 years of age at the time of signing ICF.
Contraception at least 90 days after last dose of surovatamig or 4 months after last dose of vincristine, and 6 months after the last dose of cyclophosphamide, or doxorubicin.
Histologically confirmed diagnosis of previously untreated large B-cell Lymphoma (LBCL) per WHO 2022.
R/R B-NHL after at least 1 prior lines of systemic therapy.
International Prognostic Index (IPI) 2-5.
Histologically confirmed diagnosis of previously untreated large B-cell Lymphoma (LBCL) per WHO 2022.
IPI score of 2 to 5.

Exclusion Criteria

Master Exclusion Criteria applicable to all substudies:
Central nervous system (CNS) lymphoma.
Surgery within 14 days of study drug.
Clinically significant cardiovascular (CV) disease.
Unresolved Grade \>2 AEs from prior anticancer therapy (except alopecia or fatigue).
Any systemic therapy within 5 half-lives or 21 days (whichever is shorter) prior to treatment.
Radiation therapy within 28 days.
Prior CAR T-cell therapy or autologous-haematopoietic stem cell transplant (HSCT) within 12 weeks or prior T-cell engager (TCE) within 8 weeks.
Prior Grade \> 3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) event.
Prior allogeneic HSCT or solid organ transplantation within 24 weeks of starting Cycle 1 Day 1.
Active, significant, uncontrolled infection or autoimmune disease requiring systemic therapy including participants with known history of haemophagocytic lymphohistiocytosis (HLH). Substudy 1 Specific Exclusion Criteria:
CLL/SLL transformation to more aggressive form of lymphoma.
Cohort 1B: bleeding diathesis, CYP3A inhibitor or inducer, history of ICH or stroke within 24 weeks, GI malabsorption, receiving vitamin K antagonist. Substudy 3 Specific Exclusion Criteria:
Mediastinal grey-zone lymphoma, Burkitt, Richter's transformation, primary effusion large B-cell lymphoma (LBCL).
Cumulative dose of anthracycline \>150 mg/m2.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Brunswick?

Yes, this clinical trial (NCT06564038) has an active research site in New Brunswick, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

B-cell Lymphoma Treatment Options in New Brunswick, NJ

If you're searching for b-cell lymphoma treatment options in New Brunswick, NJ, this clinical trial (NCT06564038) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Brunswick research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced b-cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all b-cell lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in New Brunswick, NJ

See all lymphoma clinical trials recruiting in New Brunswick — not just this study.

Browse Lymphoma Trials in New Brunswick →

Browse More Trials by Condition

Lymphoma TrialsDiffuse Large B-Cell Lymphoma TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in New Brunswick?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Brunswick, NJ